Actively Recruiting
Phase II Study Evaluating BL-B01D1 Alone and Combined With Lenvatinib, PD-1 Antibody, and Bevacizumab for Advanced Liver Cancer
Led by Sichuan Baili Pharmaceutical Co., Ltd. · Updated on 2026-06-10
74
Participants Needed
1
Research Sites
30 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the effectiveness and safety of BL-B01D1 alone and in combination with other drugs in patients with advanced hepatocellular carcinoma, a serious liver cancer. This Phase II clinical trial aims to explore multiple treatment options including BL-B01D1 combined with lenvatinib, PD-1 monoclonal antibody, and bevacizumab. Participants receive BL-B01D1 through intravenous infusion in 3-week cycles. Some participants may also receive lenvatinib orally daily or additional infusions of PD-1 monoclonal antibody and bevacizumab during these cycles. Treatment continues for as many cycles as the participant benefits, or until disease progression or unacceptable side effects occur. Throughout the study, participants are monitored for their response to treatment using measures like objective response rate and progression-free survival, over up to 24 months. Safety is tracked by observing adverse events. Participants undergo evaluations including tumor assessments and lab tests during the treatment period to assess outcomes and manage side effects.
CONDITIONS
Brief Title
A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
Research Team
S
Sa Xiao, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
